MarketBeat on MSN

Belite Bio eyes priority FDA review as tinlarebant targets Stargardt disease

3 Lesser-Known Healthcare Names With Major Upside in Store Belite Bio (NASDAQ:BLTE) Chief Medical Officer Hendrik Scholl said ...